XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency 
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) ("Rapid Therapeutic" or the "Company"),...
Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry’s largest...
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital...
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
Acerus Announces Amendments to Loan Facility
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it...
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal...
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained...
CloudMD Announces Cost Optimization and Operational Integration Activities
Identification and elimination of $7.5 million of annualized run-rate costs, focusing on future growth and sustainable profitabilityCost optimization activities will...
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show...
Auxly Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"),...
OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Renalytix announces a $30.0 million financing package
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA,...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
Amryt Supports World Lipodystrophy Day – March 31, 2022
Amryt Supports World Lipodystrophy Day - March 31, 2022 DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (Nasdaq: AMYT), a...
ObsEva Annual Report 2021
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – March 31, 2022 – ObsEva SA (NASDAQ:...
BioNTech Announces ADS Repurchase Program
MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it...
XORTX Files IND with US FDA
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX...
Delota Acquires $11.13M of Its Own Debt
Vaughan, Ontario--(Newsfile Corp. - March 31, 2022) - Delota Corp. (TSXV: LOTA) ("Delota" or the "Company"), an established Canadian cannabis...